Morning Overview on MSN
The FDA approved a cell therapy to curb a deadly complication of stem-cell transplants
Children who survive a stem-cell transplant only to watch their own donor cells attack their organs now have a ...
Morning Overview on MSN
The FDA cleared donor immune cells to shield blood-cancer patients from deadly complications
Adults with blood cancers who need a stem-cell transplant from a matched donor now have a new option to prevent one of the ...
The impact of the use of hypomethylating agents prior to reduced intensity conditioning allogeneic bone marrow transplant among patients with MDS. This is an ASCO Meeting Abstract from the 2025 ASCO ...
WIVB Buffalo on MSN
Roswell Park touts success with new approach for stem-cell transplants
BUFFALO, N.Y. (WIVB) — A new approach regarding stem-cell transplants has resulted in “exceptionally high” one-year overall ...
Tregzi (clinically known as Orca-T) is an allogeneic cellular immunotherapy consisting of purified regulatory and conventional T cells.
New York center hits survival with a 92.6% one-year rate for first-time allogeneic stem cell transplants, surpassing national benchmarks.
A stem-cell transplant study reported more than 15 years of treatment-free remission in two patients with NMOSD, a rare nerve disorder.
First successful allogeneic stem cell transplant using deceased donor in blood cancer clinical trial
For the first time ever, a patient has received an allogeneic stem cell transplant using a deceased donor graft as part of a blood cancer clinical trial at Huntsman Cancer Institute at the University ...
Two patients remained relapse-free for over 15 years after a stem cell transplant for NMOSD. Could this change autoimmune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results